<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02815137</url>
  </required_header>
  <id_info>
    <org_study_id>CHB 16.02</org_study_id>
    <nct_id>NCT02815137</nct_id>
  </id_info>
  <brief_title>Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma</brief_title>
  <acronym>XPO1</acronym>
  <official_title>Prevalence, Kinetic and Prognostic Value of XPO1 E571K Mutation Detection in Plasma Cell-free DNA From Patients Xith Classical Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Henri Becquerel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the XPO1 E571K mutation could be used as&#xD;
      molecular residual disease biomarker in classical Hodgkin's lymphoma. To determine the&#xD;
      interest of the mutation assessment by digital Polymerase Chain Reaction, sensitivity and&#xD;
      specificity after 2 courses of chemotherapy (C2) will be compared with the deltaSUVmax&#xD;
      determined by Positron Emission Tomography after C2 and at end of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A research team of Centre Henri Becquerel recently detected an unexpected recurrent point&#xD;
      mutation of XPO1 (exportin 1) (also known as Chromosome Region Maintenance 1) located in exon&#xD;
      15 (c.1711G&gt;A) leading to the Glu571Lys (p.E571K) missense substitution in&#xD;
      relapsed/refractory (R/R) Primary Mediastinal Large B-cell Lymphoma (PMBL) patients included&#xD;
      in the LYSA LNH03 trial program and in classical Hodgkin's Lymphoma patients. It was found&#xD;
      recurrent XPO1 E571K mutations in a large cohort of 94 patients with classical Hodgkin's&#xD;
      lymphoma. This observation is new and could add new information on driver events and&#xD;
      tumorigenesis in this disease. In total, 24.2 % of the patients with classical Hodgkin's&#xD;
      lymphoma harbored the XPO1 E571K mutation. It is remarkable that 29% of all XPO1 mutations&#xD;
      were only found in the plasma but not in the tumor because of the well-known tumor cell&#xD;
      sparsity in Hodgkin's lymphoma. In this particular disease, highly sensitive techniques like&#xD;
      digital Polymerase Chain Reaction and targeted Next-Generation Sequencing are essential to&#xD;
      highlight low frequency mutations. The research team of the Centre Henri Becquerel have&#xD;
      identified a trend toward unfavorable prognostic impact in terms of progression-free survival&#xD;
      in patients with detectable XPO1 E571K mutation in plasma cell-free DNA at the end of&#xD;
      treatment, which could prove to be statistically significant in a larger cohort. It was&#xD;
      observed that 57% of patients who ultimately relapsed were positive in the plasma after end&#xD;
      of therapy. It remains to be established whether this mutation adds new relevant value as&#xD;
      compared to Positron Emission Tomography-scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>If the mutation can be used as a molecular minimal residual disease biomarker</measure>
    <time_frame>56 days</time_frame>
    <description>Comparison of the sensitivity and specificity of the detection of the mutation between delta Standard Uptake Value max (SUV max) determined by PET after two courses of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetic of allele frequency decrease</measure>
    <time_frame>224 days</time_frame>
    <description>difference between the variant allele fraction at the end of treatment and at the diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of Deauville scale</measure>
    <time_frame>224 days</time_frame>
    <description>Difference of metabolic parameter in TEP between the end of treatment and the diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time between the inclusion and the date of progression or death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>XPO1 E571K mutation detection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Determination of mutation of XPO1571K in patient with classical hodgkin Lymphoma by digital PCR on blood samples and biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Digital Polymerase Chain Reaction</intervention_name>
    <description>Determination of mutation of XPO1 E571K by digital PCR in blod sample of patient with classical hodgkin lymphoma</description>
    <arm_group_label>XPO1 E571K mutation detection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
          -  Pathologically confirmed, recent diagnosis of classical Hodgkin Lymphoma&#xD;
&#xD;
          -  treatment planned with Adriamycin Bleamycin Vinblastine Dacarbazine (ABVD) or&#xD;
             Bleomycin Etoposide Adriamycin Cyclophosphamide Vincristine Procarbazine Prednisone&#xD;
             (BEACOPP) regimen (and radiotherapy if applicable)&#xD;
&#xD;
          -  all stages (Ann Arbor I - IV)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Patient affiliated or beneficiary of a benefit system&#xD;
&#xD;
          -  untreated patient (no corticosteroids or chemotherapy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  Treatment by ABVD or BEACOPP not indicated&#xD;
&#xD;
          -  Previously treated Hodgkin lymphoma (including corticosteroids)&#xD;
&#xD;
          -  Patients who are pregnant or lactating&#xD;
&#xD;
          -  Active Hepatitis B or Hepatitis C infection&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection - Patient with no social protection&#xD;
&#xD;
          -  Patient under tutorship or curatorship&#xD;
&#xD;
          -  Patient not affiliated of beneficiary of a benefit system&#xD;
&#xD;
          -  Medical contraindication to PET/CT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice JARDIN, PUPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Henri Becquerel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice JARDIN, PUPH</last_name>
    <phone>+33232082465</phone>
    <email>fabrice.jardin@chb.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Doriane RICHARD, PhD</last_name>
    <phone>+33232082985</phone>
    <email>doriane.richard@chb.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice JARDIN, PUPH</last_name>
      <phone>+33232082465</phone>
      <email>fabrice.jardin@chb.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>July 20, 2018</last_update_submitted>
  <last_update_submitted_qc>July 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Digital PCR</keyword>
  <keyword>classical</keyword>
  <keyword>Hodgkin Lymphoma</keyword>
  <keyword>mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

